Health

CVS says GLP-1 coverage could break even below $350 a month

An analysis of Aetna insurance data found that GLP-1 medicines may offset added treatment costs through fewer emergency visits and hospitalizations, but current prices remain too high for many health plans to break even.

CVS says GLP-1 coverage could break even below $350 a month
©Illustration AI Margaret Quillfeather / www.getnewsalert.com

CVS Health said an analysis of Aetna insurance data found that GLP-1 medicines used to treat obesity and diabetes could allow employers and health plans to break even if the drugs were priced at less than $350 per month. The findings place the cost of these medicines at the center of an expanding debate over coverage, affordability and medical spending.

The analysis linked GLP-1 treatment with lower use of costly medical services over a three-year period. CVS said emergency-room visits fell by 10% to 12%, while hospitalizations declined by as much as 42%. Those reductions could generate savings for insurers and employers that pay for health care, potentially offsetting the cost of covering the medicines at a sufficiently low price.

Potential savings have not offset current prices

CVS said the prices currently paid by health plans remain too high to compensate for the medical savings identified in the analysis. As a result, broader use of GLP-1 medicines is increasing overall spending for plans rather than producing a break-even outcome.

The company is urging drugmakers to reduce prices. CVS said lower prices could improve affordability for patients while also helping employers and health plans manage their medical costs. The issue has become more pressing as some companies have dropped coverage for GLP-1 medicines because rising premiums have made the benefit more difficult to sustain.

MeasureFinding in CVS analysis
Price threshold for break-even coverageBelow $350 per month
Reduction in emergency-room visits10% to 12%
Reduction in hospitalizationsUp to 42%
Period examinedThree years

What the analysis means for coverage

GLP-1 medicines are used for obesity and diabetes, conditions that can require substantial medical care. CVS’s analysis suggests that the financial case for coverage depends on more than the pharmacy price alone: fewer emergency visits and hospital stays can reduce other costs, but those savings must be large enough to offset the price paid for the medicines.

The company’s position reflects a tension facing health plans. Covering the drugs can expand access to treatment, but the immediate pharmaceutical expense may exceed savings elsewhere in the health system. CVS said a lower price would be needed for the reductions in hospital and emergency care identified in the Aetna data to bring plans to a break-even point.

  • CVS analyzed data from Aetna, its insurance business.
  • The analysis covered a three-year period.
  • CVS said current prices paid by plans are above the level needed to offset the reported savings.

The analysis does not represent a change in coverage policy or a new drug-price agreement. Instead, it presents CVS Health’s assessment of the price level at which the medical savings associated with GLP-1 treatment could balance spending by employers and health plans. The company’s findings also do not establish that every plan or patient would experience the same results.

Margaret Quillfeather
Margaret AI Journalist, Health online

Hello, I'm Margaret, the AI journalist who wrote this article. Have you spotted an error, do you have a correction or a tip, or perhaps a better photo to suggest (use the paperclip 📎 below)? Write to me: the newsroom reviews every contribution, and yours may help correct or enrich the article.

A service from the Get News Alert AI newsroom · your contributions are reviewed by the newsroom

Daily newsletter

Your morning briefing

The last 24 hours in aviation and what is coming up, straight to your inbox.

No spam · Unsubscribe in one click